Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Other Operating Expenses (2018 - 2022)

Historic Other Operating Expenses for Dexcom (DXCM) over the last 7 years, with Q4 2022 value amounting to -$5.7 million.

  • Dexcom's Other Operating Expenses fell 10672.17% to -$5.7 million in Q4 2022 from the same period last year, while for Sep 2023 it was -$5.7 million, marking a year-over-year decrease of 10629.83%. This contributed to the annual value of $87.1 million for FY2021, which is 338400.0% up from last year.
  • Per Dexcom's latest filing, its Other Operating Expenses stood at -$5.7 million for Q4 2022, which was down 10672.17% from $1.8 million recorded in Q3 2022.
  • In the past 5 years, Dexcom's Other Operating Expenses registered a high of $217.7 million during Q4 2018, and its lowest value of -$5.7 million during Q4 2022.
  • Over the past 5 years, Dexcom's median Other Operating Expenses value was $1.8 million (recorded in 2022), while the average stood at $30.7 million.
  • In the last 5 years, Dexcom's Other Operating Expenses soared by 4.1943040000001e17% in 2020 and then plummeted by 10672.17% in 2022.
  • Quarter analysis of 5 years shows Dexcom's Other Operating Expenses stood at $217.7 million in 2018, then plummeted by 100.0% to -$0.0 in 2019, then soared by 4194304000000100.0% to $2.5 million in 2020, then skyrocketed by 3292.0% to $84.8 million in 2021, then tumbled by 106.72% to -$5.7 million in 2022.
  • Its Other Operating Expenses was -$5.7 million in Q4 2022, compared to $1.8 million in Q3 2022 and $1.9 million in Q2 2022.